BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+3.33%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$7.83B
AUM Growth
+$7.83B
(-1.8%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
2%
Top 10 Holdings %
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
12
Closed
5
Top Buys
| 1 |
Insmed
INSM
|
$217M |
| 2 |
Summit Therapeutics
SMMT
|
$181M |
| 3 |
Alkermes
ALKS
|
$101M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$90.2M |
| 5 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$20.8M |
Top Sells
| 1 |
Incyte
INCY
|
$330M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$62.1M |
| 3 |
Roivant Sciences
ROIV
|
$48.8M |
| 4 |
Akero Therapeutics
AKRO
|
$37.9M |
| 5 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$37.5M |
Sector Composition
| 1 | Healthcare | 98.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Prelude Therapeutics
PRLD
$69.1M
| $38.6M | 0.49% |
10,123,824
| – | – |
|
27
IDEAYA Biosciences
IDYA
$2.26B
| $37.3M | 0.48% |
1,062,123
| – | – |
|
28
Cerus
CERS
$251M
| $34.3M | 0.44% |
19,477,339
| – | – |
|
29
Sera Prognostics
SERA
$129M
| $32.2M | 0.41% |
5,434,399
| – | – |
|
30
Krystal Biotech
KRYS
$4.35B
| $31.2M | 0.4% |
169,934
| – | – |
|
31
Celcuity
CELC
$2.3B
| $30.7M | 0.39% |
1,874,978
+322,500
| +21% | +$5.28M |
|
|
32
Roivant Sciences
ROIV
$8.6B
| $29.6M | 0.38% |
2,798,716
-4,615,118
| -62% | -$48.8M |
|
|
IGMS
33
DELISTED
IGM Biosciences
IGMS
| $28.1M | 0.36% |
4,090,316
+1,994
| +0% | +$13.7K |
|
|
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $28M | 0.36% |
683,588
-916,412
| -57% | -$37.5M |
|
|
35
Akero Therapeutics
AKRO
$3.65B
| $25.7M | 0.33% |
1,097,082
-1,616,123
| -60% | -$37.9M |
|
36
Dyne Therapeutics
DYN
$1.92B
| $23.7M | 0.3% |
672,096
+387,096
| +136% | +$13.7M |
|
|
ALMS
37
Alumis Inc. Common Stock
ALMS
$483M
| $20.8M | 0.27% |
+1,562,500
| New | +$20.8M |
|
38
Monte Rosa Therapeutics
GLUE
$309M
| $18.4M | 0.24% |
4,916,095
| – | – |
|
39
Merus
MRUS
$5.04B
| $17.8M | 0.23% |
+300,000
| New | +$17.8M |
|
40
Neurogene
NGNE
$284M
| $16.6M | 0.21% |
456,015
| – | – |
|
41
TScan Therapeutics
TCRX
$106M
| $16.3M | 0.21% |
2,784,792
| – | – |
|
42
Sana Biotechnology
SANA
$759M
| $13M | 0.17% |
2,380,949
| – | – |
|
43
Immunovant
IMVT
$2.91B
| $12.3M | 0.16% |
464,718
+39,709
| +9% | +$1.05M |
|
44
Xencor
XNCR
$594M
| $10.3M | 0.13% |
545,431
| – | – |
|
45
Neumora Therapeutics
NMRA
$283M
| $10.2M | 0.13% |
1,034,600
+400,749
| +63% | +$3.94M |
|
46
Fate Therapeutics
FATE
$115M
| $9.83M | 0.13% |
2,997,772
+1,179,591
| +65% | +$3.87M |
|
|
TSVT
47
DELISTED
2seventy bio
TSVT
| $9.62M | 0.12% |
2,497,526
| – | – |
|
48
Biomea Fusion
BMEA
$114M
| $9.49M | 0.12% |
2,108,949
| – | – |
|
49
Celldex Therapeutics
CLDX
$1.57B
| $9.17M | 0.12% |
247,644
| – | – |
|
50
Taysha Gene Therapies
TSHA
$791M
| $8.97M | 0.11% |
4,004,756
| – | – |
|